Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Bio-Rad Laboratories, Inc.NYSE: BIO
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures declines year over year
Q2 FY2026 capital expenditures of $32M (cash outflow) fell 30.0% year over year, behind the -25.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 6.7% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Capital expenditures amounted to 6.1% of revenue in FY2025, down 1.3 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -30.0% toward the trailing-twelve-month pace of -25.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (157.6M) USD
- Year-over-year change
- +16.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (157.6M) | +16.6% |
| FY2024 | 2024-12-31 | (189M) | -20.6% |
| FY2023 | 2023-12-31 | (156.68M) | -37.2% |
| FY2022 | 2022-12-31 | (114.16M) | +14.6% |
| FY2021 | 2021-12-31 | (133.75M) | — |
Capital Expenditures vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 capital expenditures of $139.5M is the 3rd largest of the 11 companies compared; the peer median is $29.74M.
- Its year-over-year change of -25.3% is the 8th highest of 11, against a peer median of -13.9%.
- Capital expenditures amounts to 5.4% of revenue for BIO, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.73B | +12.2% | -12.1% | 3.6% | |
| LTM Sep 2026 | $1.13B | -13.0% | +0.1% | 4.4% | |
| LTM Jun 2026 | $139.5M | -25.3% | +11.3% | 5.4% | |
| LTM Jun 2026 | $96.5M | -17.2% | -2.4% | 2.8% | |
| LTM Jul 2026 | $69.52M | -14.8% | -5.0% | 2.4% | |
| LTM Sep 2026 | $30.08M | -11.2% | -8.6% | 4.8% | |
| LTM Sep 2026 | $29.4M | +8.1% | -9.0% | 2.4% | |
| LTM Jun 2026 | $24.09M | -7.9% | -43.9% | 3.1% | |
| LTM Jun 2026 | $9.85M | -58.2% | -8.4% | 4.7% | |
| LTM Mar 2026 | $4.37M | -49.8% | -45.7% | 2.7% | |
| LTM Mar 2026 | $3.82M | -69.8% | +29.5% | 4.4% | |
| Peer median (excluding BIO) | $29.74M | -13.9% | -8.5% | 3.4% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.25B | (3.63B) | (637.3M) | (1.84B) | 759.9M |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 51.2M | 60.9M | 61.3M | 62.3M | 58M |
| Change in Working Capital | 1.14B | (1.61B) | (432.8M) | (620.8M) | 272.4M |
| Accounts Receivables | (20.4M) | (87.4M) | 11.4M | 16.2M | 19.6M |
| Inventory | 46.1M | (158.8M) | (46.3M) | 8.5M | 68.9M |
| Accounts Payables | 69.9M | (94.2M) | (51.8M) | (40.9M) | (100K) |
| Other Working Capital | 1.05B | (1.27B) | (346.1M) | (604.6M) | 184M |
| Other Non-Cash Items | (4.92B) | 5.23B | 1.24B | 2.71B | (723.5M) |
| Operating Cash Flow | 669.46M | 194.45M | 374.94M | 455.2M | 532.2M |
| Capital Expenditures | (133.75M) | (114.16M) | (156.68M) | (189M) | (157.6M) |
| Acquisitions (Net) | (125.52M) | (99.39M) | 2.5M | 0 | (218.4M) |
| Purchases of Investments | (851.63M) | (2.06B) | (689.04M) | (1.28B) | (669.3M) |
| Sales of Investments | 766.9M | 1.07B | 863.22M | 1.31B | 62M |
| Other Investing Activities | (453.39M) | (1.21M) | 211K | (23.3M) | 793.6M |
| Investing Cash Flow | (797.38M) | (1.21B) | 20.21M | (160.2M) | (189.7M) |
| Debt Repayment | (3.02M) | 1.19B | (467K) | (400K) | (500K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 15.8M |
| Common Stock Repurchased | (50M) | (215.68M) | (428.73M) | (203.6M) | (295.5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.41M) | 3.55M | 3.55M | (14.8M) | (3M) |
| Financing Cash Flow | (55.43M) | 973.58M | (425.65M) | (218.8M) | (283.2M) |
| Effect of Forex Changes | (12.64M) | 2.98M | 321K | 9.2M | (19M) |
| Net Change in Cash | (195.98M) | (36.59M) | (30.18M) | 85.4M | 40.3M |
| Free Cash Flow | 535.72M | 80.29M | 218.26M | 266.2M | 374.6M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.